MedTrace Logo

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

NCT04381884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-10-05

No results posted yet for this study

Summary

In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral replication in cell cultures has been published, and the use of this medication seems to be potentially useful for the therapy. IVM safety profile and IVM wide spectrum enables to move forward with the investigation in patients infected by SARS-CoV-2 as a proof-of-concept of its possible use in the management of patients with COVID-19, given the current pandemic situation.

Conditions

  • COVID-19 Drug Treatment

Interventions

DRUG

IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.

IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.

Sponsors & Collaborators

  • Universidad Nacional de Salta

    collaborator OTHER

  • Centro de Investigación Veterinaria Tandil CIVETAN

    collaborator UNKNOWN

  • Hospital de Pediatría Prof Dr. Juan P. Garrahan

    collaborator UNKNOWN

  • Universidad Nacional de Quilmes

    collaborator UNKNOWN

  • Laboratorio Elea Phoenix S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-18
Primary Completion
2020-09-29
Completion
2020-09-29

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04381884 on ClinicalTrials.gov